Results 91 to 100 of about 5,634,776 (298)

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

The hemodynamic repercussions of the autonomic modulations in growth-restricted fetuses

Alexandria Journal of Medicine, 2017
Objectives: Idiopathic fetal growth restriction is considered to be associated with hemodynamic abnormalities. The study was aimed to the investigation of the relationship between fetal and maternal autonomic balance, arterial and venous hemodynamic ...
Igor Victorovich Lakhno
doaj   +1 more source

Epigenetic silencing of the liver‐specific lncRNA LUNAR promotes liver cancer progression via NOTCH activation

Molecular Oncology, EarlyView.
LUNAR is a liver‐specific long noncoding RNA (lncRNA) that is highly expressed in normal liver but becomes epigenetically silenced in hepatocellular carcinoma through promoter hypermethylation. Loss of LUNAR is associated with NOTCH activation, epithelial–mesenchymal transition, and metastasis, whereas restoring LUNAR restrains metastatic progression ...
Se Ha Jang, Hyung Seok Kim, Geum Ok Baek, Moon Gyeong Yoon, Su In Lee, Jee‐Yeong Jeong, Ji Eun Han, Soon Sun Kim, Jae Youn Cheong, Jung Woo Eun   +9 more
wiley   +1 more source

Targeting transcription factors associated with hemoglobinopathies: Lessons from successful interventions and implications for cancer

Molecular Oncology, EarlyView.
This review summarizes the transcription factors, repressive chromatin‐modifying complexes, and epigenetic mechanisms that control fetal hemoglobin repression. Notably, many regulators of γ‐globin silencing also function in transcriptional and epigenetic networks that drive cancer, highlighting opportunities to translate advances in hemoglobinopathy ...
Meigen Yu, Puspa Das, Xing Zhang, Xiaodong Cheng   +3 more
wiley   +1 more source

Association of maternal and umbilical cord blood leptin concentrations and abnormal color Doppler indices of umbilical artery with fetal growth restriction

International Journal of Reproductive BioMedicine, 2017
Background: Fetal growth restriction (FGR) is a condition with heterogeneous pathophysiology which characterized by fetal weight less than the tenth percentile for gestational age.
Elahe Zareaan, Mitra Heidarpour, Elham Kargarzadeh   +2 more
doaj   +2 more sources

Maternal serum copeptin as a marker for fetal growth restriction

Middle East Fertility Society Journal, 2013
Objectives: Copeptin is a hormone of endogenous stress. The aim was to evaluate whether the measurement of maternal serum copeptin is useful for differentiation between fetal growth retardation and constitutionally small fetuses among small for ...
Ashraf A. Foda, Ibrahim A. Abdel Aal
doaj   +1 more source

CEACAM1 participation in breast cancer progression

Molecular Oncology, EarlyView.
In invasive breast cancer (BC), CEACAM1 shifts from an apical to a uniform membranous/cytoplasmic pattern, or is lost, as tumors dedifferentiate, inversely tracking the Ki‐67 proliferative index. In MCF‐7 cells, only CEACAM1‐4L suppresses proliferation, repressing cell cycle and growth factor genes.
Mykola Lyndin, Irina Kube‐Golovin, Anatolii Romaniuk, Gunther Wennemuth   +3 more
wiley   +1 more source

Investigating the Potential of Sildenafil in Mitigating Fetal Growth Restriction: A Study on Experimentally Restricted Fetal Growth Rats [PDF]

Iranian Journal of Veterinary Surgery
Intrauterine growth restriction (IUGR) is a common pregnancy complication. Sildenafil is also emerging as a potential candidate for the treatment of IUGR.
Ghasem Akbari, Siamak Kazemi-Darabadi, Mehdi Basaki, Meysam Karami, Pardis Elmdoustazar   +4 more
doaj   +1 more source

Maternal and fetal cord blood lipids in intrauterine growth restriction

, 2012
Small for gestational age neonates (SGA) could be subdivided into two groups according to the underlying causes leading to low birth weight. Intrauterine growth restriction (IUGR) is a pathologic condition with diminished growth velocity and fetal ...
Piroth, Daniela, Bauerschlag, Dirk O, Bruno, Benjamin, Brieger, Meike, Rath, Werner, Piroth, Daniela Melanie, Fitzner, Christina, Schiessl, Barbara, Pecks, Ulrich, Maass, Nicolai, Orlikowsky, Thorsten, Bauerschlag, Dirk   +11 more
core   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source